Want to see HK:9995 full AI Analyst Report?
Top Page
RemeGen Co. Ltd. Class H
(9995)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$89.00
▲(7.88% Upside)
Action:Upgraded
Date:08/27/26
The score is driven mainly by strong TTM financial performance (profitability and cash flow turnaround), tempered by historical volatility that creates sustainability risk. Technical indicators are mixed-to-weak (below 100/200-day averages and negative MACD), while valuation appears reasonable on a low-teens P/E.
Positive Factors
Revenue Growth
The sharp TTM revenue increase indicates substantially stronger product demand or commercialization performance. If sustained, this expansion can improve operating leverage, support pipeline investment, and strengthen RemeGen’s competitive position.
Negative Factors
Earnings Volatility
The rapid shift from substantial losses to very high profitability makes current earnings harder to compare and forecast. Such volatility raises the risk that recent performance reflects an unstable stage of the biotech business rather than a durable baseline.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp TTM revenue increase indicates substantially stronger product demand or commercialization performance. If sustained, this expansion can improve operating leverage, support pipeline investment, and strengthen RemeGen’s competitive position.
Read all positive factors
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$67.94B
Dividend YieldN/A
Average Volume (3M)3.52M
Price to Earnings (P/E)12.0
Beta (1Y)1.50
Revenue Growth305.94%
EPS GrowthN/A
CountryHK
Employees3,145
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)10.37
Shares Outstanding208,581,240
10 Day Avg. Volume3,327,645
30 Day Avg. Volume3,517,997
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)10.96
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$116.49Price Target Upside41.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)7.44
Revenue Forecast (FY)HK$7.42B
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
Company Description
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telit...
How the Company Makes Money
RemeGen primarily makes money through (1) product sales of its approved therapies, where revenue is recognized from selling finished drug products to customers (e.g., hospitals, pharmacies, and/or distributors) within its commercialization territo...
RemeGen Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
78
Positive
Cash Flow
81
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.95B | 3.24B | 1.72B | 1.08B | 767.77M | 1.42B |
| Gross Profit | 7.37B | 2.84B | 1.37B | 822.99M | 497.84M | 1.36B |
| EBITDA | 5.09B | 431.72M | -1.19B | -1.25B | -805.70M | 402.05M |
| Net Income | 5.78B | 709.65M | -1.47B | -1.51B | -997.84M | 276.26M |
Balance Sheet | ||||||
| Total Assets | 9.85B | 7.25B | 5.50B | 5.53B | 6.02B | 4.16B |
| Cash, Cash Equivalents and Short-Term Investments | 5.14B | 2.42B | 759.53M | 709.07M | 2.19B | 1.76B |
| Total Debt | 310.96M | 2.20B | 2.67B | 1.26B | 165.03M | 102.78M |
| Total Liabilities | 1.45B | 3.55B | 3.51B | 2.09B | 1.04B | 712.79M |
| Stockholders Equity | 8.31B | 3.61B | 1.99B | 3.44B | 4.98B | 3.45B |
Cash Flow | ||||||
| Free Cash Flow | 4.35B | -140.08M | -1.38B | -2.35B | -2.02B | -353.71M |
| Operating Cash Flow | 4.50B | 54.75M | -1.11B | -1.50B | -1.26B | 263.63M |
| Investing Cash Flow | -2.11B | -203.49M | -248.24M | -817.65M | -841.56M | -637.95M |
| Financing Cash Flow | -2.11B | 537.67M | 1.39B | 978.31M | 2.43B | -626.90M |
RemeGen Co. Ltd. Class H Technical Analysis
Negative
82.50
Price Trends
81.63
Negative
84.98
Negative
85.58
Negative
Market Momentum
-0.28
Negative
48.58
Neutral
53.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9995, the sentiment is Negative. The current price of 82.5 is above the 20-day moving average (MA) of 80.63, above the 50-day MA of 81.63, and below the 200-day MA of 85.58, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 48.58 is Neutral, neither overbought nor oversold. The STOCH value of 53.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9995.
RemeGen Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$67.94B | 11.96 | 128.12% | ― | 305.94% | ― | |
71 Outperform | HK$22.97B | 25.34 | 12.35% | ― | 117.39% | ― | |
64 Neutral | HK$38.22B | 37.75 | 20.41% | ― | 32.63% | 8.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$93.22B | -83.32 | -10.86% | ― | 42.47% | -15.80% | |
46 Neutral | HK$8.55B | -43.68 | -10.27% | ― | -31.77% | -177.01% | |
46 Neutral | HK$34.66B | -78.10 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:9995
RemeGen Co. Ltd. Class H
78.70
-18.05
-18.66%
HK:9926
Akeso, Inc.
96.00
-46.50
-32.63%
HK:9966
Alphamab Oncology
8.61
-2.18
-20.25%
HK:9969
InnoCare Pharma Ltd.
14.80
-3.13
-17.46%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.66
-17.74
-50.11%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
65.55
-23.15
-26.10%
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Delivers Surging Interim Revenue as Key Biologic Therapies Secure New Approvals and Milestones
Aug 24, 2026
RemeGen Co., Ltd. reported a sharp rise in interim revenue to RMB5,850.2 million for the six months ended June 30, 2026, a 435.74% increase year-on-year driven by robust sales of its commercial-stage drugs telitacicept and disitamab vedotin, as we...
RemeGen Sets Out Board Structure and Key Governance Committees
Aug 24, 2026
RemeGen Co., Ltd. has announced the current composition of its board of directors, comprising five executive directors, one non-executive director and three independent non-executive directors. The chairman of the board, together with the employee...
RemeGen Commits US$100 Million of Idle Funds to OCBC Wealth Products in Discloseable Transaction
Aug 18, 2026
RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong, develops and commercializes innovative biologic therapies for autoimmune and oncology indications across domestic and global markets. The company leverages its listing t...
RemeGen Sets Board Meeting to Approve Interim 2026 Results
Aug 12, 2026
RemeGen Co., Ltd. has scheduled a board meeting for August 24, 2026 to review and approve the interim results for the six months ended June 30, 2026. The company also plans to publish these interim results following board approval, a step that wil...
RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal
Aug 5, 2026
RemeGen Co., Ltd. has issued an inside information announcement estimating a sharp improvement in its financial performance for the six months ended June 30, 2026, under China Accounting Standards. The company expects operating revenue of about RM...
RemeGen Deploys Idle Funds Into SPDB Wealth Products in Discloseable Transaction
Jul 2, 2026
RemeGen Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, is leveraging its idle self-owned funds and A-share proceeds to optimize cash management. The firm’s strategy includes allocating significant surplus capital into bank ...
RemeGen Shareholders Back All Resolutions at 2025 AGM
Jun 16, 2026
RemeGen Co., Ltd. held its 2025 annual general meeting in Yantai, with shareholders representing about 41.5% of total issued A and H shares in attendance, either in person or by proxy. All directors were present, and no shareholders were required ...
RemeGen Clarifies Board Composition and Committee Roles
Jun 16, 2026
RemeGen Co., Ltd. has disclosed the current composition of its board of directors, which includes five executive directors, one non-executive director, and three independent non-executive directors, with Wang Weidong serving as chairman. The compa...
RemeGen Wins Conditional China Nod for Telitacicept in IgA Nephropathy
Jun 8, 2026
RemeGen has secured conditional marketing approval from China’s National Medical Products Administration for a new indication of its biologic Telitacicept Injection to treat adult patients with primary IgA nephropathy at risk of disease prog...
RemeGen Wins NMPA Approval for New Telitacicept Indication in Sjögren’s Disease
Jun 8, 2026
RemeGen Co., Ltd. has secured approval from China’s National Medical Products Administration for a new indication of its biologic Telitacicept for Injection, allowing its use in adult patients with active Sjögren’s disease who are...
RemeGen boosts cash management with new RMB300 million SPDB wealth product
Jun 1, 2026
RemeGen Co., Ltd. has expanded its use of idle self-owned funds for short-term cash management, entering into a new SPDB Wealth Management Product Agreement No. 8 with the Shanghai Pudong Development Bank Yantai Branch on 1 June 2026. Under the la...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.